<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2761">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070951</url>
  </required_header>
  <id_info>
    <org_study_id>16-OBE2109-009</org_study_id>
    <nct_id>NCT03070951</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids</brief_title>
  <acronym>PRIMROSE 2</acronym>
  <official_title>A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ObsEva SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ObsEva SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the superior efficacy versus placebo
      of OBE2109 alone and in combination with add-back therapy for the reduction of heavy
      menstrual bleeding associated with uterine fibroids in premenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, randomized, parallel group, double-blind, placebo-controlled
      phase 3 study investigating the efficacy and safety of OBE2109 alone and in combination with
      add-back therapy for the treatment of uterine fibroids.

      Subjects will be randomized to one of 5 treatment groups in a 1:1:1:1:1 ratio.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Responders based on menstrual blood loss (MBL) volume reduction at Week 24</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <description>Assessed using the alkaline hematin method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amenorrhea</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Assessed using the alkaline hematin method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to amenorrhea</measure>
    <time_frame>Up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reduced menstrual blood loss</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Assessed using the alkaline hematin method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of uterine bleeding for each 28-day interval</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Assessed using the alkaline hematin method</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bone Mineral Density (BMD)</measure>
    <time_frame>From baseline up to Week 52</time_frame>
    <description>Assessed by dual-energy X-ray absorptiometry (DXA) scan</description>
  </other_outcome>
  <other_outcome>
    <measure>Endometrial biopsy</measure>
    <time_frame>From baseline up to Week 52</time_frame>
    <description>Assessed by histology</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Frequency and severity of Treatment-Emergent Adverse Events</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Uterine Fibroids</condition>
  <condition>Heavy Menstrual Bleeding</condition>
  <arm_group>
    <arm_group_label>OBE2109 dose 1 + Placebo Add-back</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OBE2109 dose 1 + Add-back</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OBE2109 dose 2 + Placebo Add-back</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OBE2109 dose 2 + Add-back</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Placebo Add-back / OBE2109 dose 3 + Add-back</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Placebo Add-back</intervention_name>
    <description>Placebo tablets and Placebo Add-back for oral administration once daily</description>
    <arm_group_label>Placebo + Placebo Add-back / OBE2109 dose 3 + Add-back</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OBE2109 + Placebo Add-back</intervention_name>
    <description>OBE2109 tablets and Placebo Add-back for oral administration once daily</description>
    <arm_group_label>OBE2109 dose 1 + Placebo Add-back</arm_group_label>
    <arm_group_label>OBE2109 dose 2 + Placebo Add-back</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OBE2109 + Add-back</intervention_name>
    <description>OBE2109 tablets and Add-back for oral administration once daily</description>
    <arm_group_label>OBE2109 dose 1 + Add-back</arm_group_label>
    <arm_group_label>OBE2109 dose 2 + Add-back</arm_group_label>
    <arm_group_label>Placebo + Placebo Add-back / OBE2109 dose 3 + Add-back</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Premenopausal woman at screening.

          -  Body Mass Index ≥ 18 kg/m2.

          -  Menstrual cycles ≥ 21 days and ≤ 40 days.

          -  Presence of uterine fibroids.

          -  Heavy menstrual blood loss for each of the 2 menstrual periods assessed at screening
             using the alkaline hematin method.

        Key Exclusion Criteria:

          -  The subject is pregnant or breast-feeding or is planning a pregnancy within the
             duration of the treatment period of the study.

          -  History of uterus surgery that would interfere with the study.

          -  The subject's condition is so severe that she will require surgery within 6 months
             regardless of the treatment provided.

          -  Undiagnosed abnormal uterine bleeding.

          -  Significant risk of osteoporosis or history of, or known osteoporosis or other
             metabolic bone disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ObsEva SA</last_name>
    <role>Study Director</role>
    <affiliation>Geneva</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chief Medical Officer</last_name>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 28, 2017</lastchanged_date>
  <firstreceived_date>February 17, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine Fibroid</keyword>
  <keyword>Leiomyomata</keyword>
  <keyword>Heavy Menstrual Bleeding</keyword>
  <keyword>HMB</keyword>
  <keyword>Heavy Uterine Bleeding</keyword>
  <keyword>Menorrhagia</keyword>
  <keyword>OBE2109 + Add-back</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
